We performed a meta-analysis of randomized controlled trials comparing LMWH versus no LMWH in women with inherited thrombophilia and prior late (≥10 weeks) or recurrent early (<10 weeks) pregnancy loss. Eight trials and 483 patients met our inclusion criteria. There was no significant difference in livebirth rates with the use of LMWH compared to no LMWH (RR 0.81, 95% CI, 0.55 to 1.19, p=0.28), suggesting no benefit of LMWH in preventing recurrent pregnancy loss in women with inherited thrombophilia. 
Introduction
Recurrent pregnancy loss, commonly defined as 3 or more consecutive miscarriages, occurs in 1% of all women, with no cause identified in half of cases 1, 2 . Inherited and acquired thrombophilias have been evaluated as a potential cause of pregnancy loss, given the importance of adequate utero-placental circulation on fetal development and survival. Coagulation activation at the maternal-fetal interface plays an important role in placental development 3 . Several meta-analyses have reported an increased risk of pregnancy loss in women with inherited thrombophilia, however, significant heterogeneity attributed to study design and the definition of recurrent pregnancy loss limits firm conclusions [4] [5] [6] [7] . Overall, inherited thrombophilias appear to be, at best, a weak contributor to late or recurrent early pregnancy loss. Our meta-analysis evaluating only prospective cohort studies reported a small increased risk of pregnancy loss in women with Factor V Leiden (FVL) (4.2%) compared to women without FVL (3.2%), suggesting a weak causal effect (OR 1.52, 95% CI, 1.06 to 2.19) 8 . There is a lack of data
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When compared to inherited thrombophilias, antiphospholipid syndrome (APS) has been more strongly and consistently associated with pregnancy loss; clinical criteria needed to make a diagnosis of APS includes pregnancy morbidity involving either one pregnancy loss ≥ 10 weeks gestation, three unexplained losses < 10 weeks gestation or other placental complications [9] [10] [11] . Unfortunately, high-quality data to support the use of prophylactic-dose low-molecular-weight heparin (LMWH) and aspirin to prevent pregnancy loss or placental complications in APS is surprisingly limited and warrants further randomized trials 12 .
For the purpose of this review, we will focus on inherited thrombophilia and the role of LMWH in preventing future pregnancy loss.
In women with an inherited thrombophilia and prior late or recurrent early pregnancy loss, we sought to determine whether the use of prophylactic-dose LMWH (+/-aspirin) reduced the risk of pregnancy loss when compared to no LMWH (+/-aspirin).
Methods

Study Selection
A systematic search of the literature was conducted on MEDLINE (1946 ( -September 2015 , EMBASE (1947 -September 2015 and EBM reviews using the Cochrane 
Data Extraction and Synthesis
Two investigators independently reviewed all abstracts and the full-text of potentially relevant studies (L.S. and M.C.). Studies were included if they met eligibility criteria outlined as follows: (1) peer-reviewed randomized controlled trials, (2) pregnant women with 1) inherited thrombophilia and 2) prior late (≥10 weeks) or recurrent early (≥2 losses <10 weeks) pregnancy loss, (3) randomly allocated to prophylactic-dose LMWH with or without aspirin, versus no LMWH with or without aspirin and (4) the primary outcome of livebirth rate was reported. Only patients with an inherited thrombophilia were included, women with a diagnosis of APS or women who did not have a thrombophilic disorder were excluded. Secondary outcomes of adverse events such as major and non-major bleeding, HIT, increased liver enzymes, skin or allergic reactions, induction of labor and cesarean section rates were recorded when available 13, 14 .
Of the eligible studies, data was extracted independently by two investigators utilizing a standardized pilot data extraction form (L.S. and M.C. Our treatment recommendations are based on the quality of available evidence, and are outlined using the Grading of Recommendations Assessment Development and Evaluation tool 21 .
Results
Our search strategy identified 1406 article records, of which 8 publications and 483 participants met eligibility criteria ( Figure 1 ) [15] [16] [17] [22] [23] [24] [25] [26] . Baseline study characteristics are depicted in .
Safety outcomes were not uniformly reported for our population of interest, all adverse events reported have been described in the context of larger clinical trials. There was not enough data available to compare 2 versus 3 or more losses in women with thrombophilia.
Discussion
In this systematic review and meta-analysis, prophylactic-dose LMWH (with or without aspirin) did not reduce the risk of pregnancy loss in women with inherited thrombophilia with prior late or recurrent early pregnancy loss, when compared to no treatment or aspirin alone. This finding was consistent across subgroups of either previous late loss (≥10 weeks) or previous recurrent early (<10 weeks) pregnancy loss. To our knowledge, this is the largest study published to date that evaluates LMWH in women with inherited thrombophilia and previous pregnancy loss, made possible by international collaboration with investigators who provided additional data in 6 of the 8 trials.
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We did not see evidence of a beneficial effect of LMWH in preventing future pregnancy loss in thrombophilic women with prior recurrent early loss. However, given our limited sample size (n=66), we cannot exclude a beneficial effect of LMWH in this subgroup.
There is an ongoing randomized controlled trial, ALIFE2 (Netherlands Trial Registration Identifier: NTR3361) that is evaluating LMWH in women with inherited thrombophilia and a history of 2 or more miscarriages and/or intrauterine fetal death, which we hope will provide definitive answers to this question 27 .
In the era of responsible testing and prescribing practices, the results of our meta-analysis provide further evidence that there is no benefit of LMWH in preventing future pregnancy loss in women with inherited thrombophilia, with the potential for adverse side effects and significant cost of LMWH 28 . By extension, this also significantly limits the benefit of thrombophilia testing in women with pregnancy loss. If LMWH intervention is not going to be offered (outside of clinical trials) then why test? One could argue that because there is a higher prevalence of inherited thrombophilia in women with prior pregnancy loss, testing offers an opportunity to identify women with thrombophilia.
However, the benefits of identifying thrombophilia would be limited to alerting these women and their health care providers to their lifetime risks of venous thrombosis with an opportunity for thromboprophylaxis during high-risk periods (including the postpartum interval). The associated cost of testing to identify one case would be significant given the weak association with pregnancy loss.
There are several limitations to our meta-analysis. We included the use of aspirin in either treatment arm, as we were primarily evaluating the role of LMWH versus no LMWH. We cannot exclude the possibility that a combined treatment effect of LMWH and aspirin was lost by combining results with LMWH alone, or that aspirin in the control group mitigated any differences seen between groups. Unfortunately, the number of patients included was too small to evaluate outcomes from trials that did not include There were also differences across trials in the types of inherited thrombophilia included and the method in which thrombophilia testing was performed. A patient-level metaanalysis could provide additional data on the outcomes for specific thrombophilias, as well as address the issue of heterogeneity in the varying definitions of pregnancy loss.
In conclusion, we found no difference in preventing future pregnancy loss with LMWH when compared to no LMWH in women with inherited thrombophilia and prior late or Favor LMWH' suggests a benefit of LMWH in preventing pregnancy loss; 'Favor Control' suggests a benefit of no LMWH in preventing pregnancy loss. *The relative risk is indeterminate because there were no pregnancy losses among the 23 women from the HAPPY trial
